Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation: a real patient data analysis in a Hong Kong teaching hospital

Chang AM, Ho JC, Yan BP, Yu CM, Lam YY, Lee VW

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23494609

DOI
10.1002/clc.22112

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Aged, 80 and over; Anticoagulants/adverse effects/economics/therapeutic use; Atrial Fibrillation/complications/diagnosis/drug therapy/economics; Benzimidazoles/adverse effects/economics/therapeutic use; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization/economics; Drug Utilization Review; Female; Health Expenditures; Hong Kong; Hospital Costs; Hospitals, Teaching/economics; Humans; Male; Middle Aged; Preventive Health Services/economics; Retrospective Studies; Stroke/diagnosis/economics/etiology/prevention & control; Treatment Outcome; Warfarin/adverse effects/economics/therapeutic use; beta-Alanine/adverse effects/analogs & derivatives/economics/therapeutic use

AccessionNumber
22013022688

Date bibliographic record published
25/06/2013